Rocket Pharmaceuticals

Rocket Pharmaceuticals is a publicly traded gene therapy company dedicated to developing curative treatments for rare genetic disorders. Its most advanced program targets Danon Disease, a life-threatening cardiac condition, with a Phase 2 pivotal trial underway. The company leverages its expertise in gene therapy platforms to build a pipeline addressing significant unmet medical needs, guided by a patient-centric philosophy and core values of trust, generosity, curiosity, and elevation.

Developer of one-time gene therapies designed to correct rare genetic disorders at the DNA level, with demonstrated clinical work in systemic and cardiac-targeted gene delivery.

9 drugs in pipeline

Rocket is a first-mover with clinical gene therapy data for Danon Disease, but may face future competition from other biotechs in cardiology. In hematology, it competes with other gene therapy developers and transplant approaches. Its differentiation lies in its focus on severe rare diseases and pioneering work in cardiac-targeted gene delivery.